- Home
- PRT vs CCEL Comparison
PRT vs CCEL Comparison
Compare PRT & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRT | CCEL |
|---|---|---|
| Founded | 2017 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Managed Health Care |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.0M | 30.9M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | PRT | CCEL |
|---|---|---|
| Price | $2.09 | $4.40 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 25.1K | 16.1K |
| Earning Date | 05-13-2026 | 04-14-2026 |
| Dividend Yield | ★ 13.45% | 4.26% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $25,384,279.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ $7.78 | $58.71 |
| Revenue Growth | N/A | ★ 9.76 |
| 52 Week Low | $1.82 | $2.72 |
| 52 Week High | $4.01 | $5.01 |
Technical Indicators
Market Signals| Indicator | PRT | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 33.40 | 60.32 |
| Support Level | $2.02 | $3.04 |
| Resistance Level | $2.32 | $4.90 |
| Average True Range (ATR) | 0.07 | 0.26 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 17.86 | 60.80 |
Price Performance
Historical ComparisonAbout PRT PermRock Royalty Trust Trust Units
PermRock Royalty Trust operates as a statutory trust. Its purpose is to own the Net Profits Interest, to distribute to the Trust unitholders cash that it receives in respect of the Net Profits Interest, and to perform certain administrative functions. The Net Profits Interest entitles the trust to receive the net profits from the sale of oil and natural gas production from the underlying properties of its trustor.
About CCEL Cryo-Cell International Inc.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.